Treatment  ||| S:0 E:10 ||| NN
of  ||| S:10 E:13 ||| IN
shizophrenic  ||| S:13 E:26 ||| JJ
patients  ||| S:26 E:35 ||| NNS
and  ||| S:35 E:39 ||| CC
rTMS  ||| S:39 E:44 ||| JJ
schizophrenia  ||| S:44 E:58 ||| NN
( ||| S:58 E:59 ||| -LRB-
SCH ||| S:59 E:62 ||| NNP
)  ||| S:62 E:64 ||| -RRB-
is  ||| S:64 E:67 ||| VBZ
a  ||| S:67 E:69 ||| DT
heterogeneous  ||| S:69 E:83 ||| JJ
syndrome  ||| S:83 E:92 ||| NN
characterized  ||| S:92 E:106 ||| VBN
by  ||| S:106 E:109 ||| IN
positive  ||| S:109 E:118 ||| JJ
and  ||| S:118 E:122 ||| CC
negative  ||| S:122 E:131 ||| JJ
symptoms ||| S:131 E:139 ||| NNS
.  ||| S:139 E:141 ||| .
Despite  ||| S:141 E:149 ||| IN
appropriate  ||| S:149 E:161 ||| JJ
medication ||| S:161 E:171 ||| NN
,  ||| S:171 E:173 ||| ,
about  ||| S:173 E:179 ||| IN
1 ||| S:179 E:180 ||| CD
/ ||| S:180 E:181 ||| CD
4  ||| S:181 E:183 ||| CD
of  ||| S:183 E:186 ||| IN
patients  ||| S:186 E:195 ||| NNS
suffer  ||| S:195 E:202 ||| VBP
for  ||| S:202 E:206 ||| IN
refractory  ||| S:206 E:217 ||| JJ
positive  ||| S:217 E:226 ||| JJ
and ||| S:226 E:229 ||| CC
/ ||| S:229 E:230 ||| NNP
or  ||| S:230 E:233 ||| CC
negative  ||| S:233 E:242 ||| JJ
symptoms ||| S:242 E:250 ||| NNS
,  ||| S:250 E:252 ||| ,
which  ||| S:252 E:258 ||| WDT
are  ||| S:258 E:262 ||| VBP
associated  ||| S:262 E:273 ||| VBN
with  ||| S:273 E:278 ||| IN
functional  ||| S:278 E:289 ||| JJ
handicap ||| S:289 E:297 ||| NN
,  ||| S:297 E:299 ||| ,
increase  ||| S:299 E:308 ||| NN
of  ||| S:308 E:311 ||| IN
duration  ||| S:311 E:320 ||| NN
and  ||| S:320 E:324 ||| CC
of  ||| S:324 E:327 ||| IN
the  ||| S:327 E:331 ||| DT
number  ||| S:331 E:338 ||| NN
of  ||| S:338 E:341 ||| IN
hospitalizations ||| S:341 E:357 ||| NNS
.  ||| S:357 E:359 ||| .
Numerous  ||| S:359 E:368 ||| JJ
studies  ||| S:368 E:376 ||| NNS
have  ||| S:376 E:381 ||| VBP
suggested  ||| S:381 E:391 ||| VBN
that  ||| S:391 E:396 ||| IN
the  ||| S:396 E:400 ||| DT
pathophysiology  ||| S:400 E:416 ||| NN
of  ||| S:416 E:419 ||| IN
auditory  ||| S:419 E:428 ||| JJ
hallucinations  ||| S:428 E:443 ||| NNS
( ||| S:443 E:444 ||| -LRB-
AH ||| S:444 E:446 ||| NNP
)  ||| S:446 E:448 ||| -RRB-
is  ||| S:448 E:451 ||| VBZ
related  ||| S:451 E:459 ||| VBN
to  ||| S:459 E:462 ||| TO
a  ||| S:462 E:464 ||| DT
hyper  ||| S:464 E:470 ||| JJ
activity  ||| S:470 E:479 ||| NN
of  ||| S:479 E:482 ||| IN
the  ||| S:482 E:486 ||| DT
left  ||| S:486 E:491 ||| JJ
temporoparietal  ||| S:491 E:507 ||| JJ
cortex  ||| S:507 E:514 ||| NNS
( ||| S:514 E:515 ||| -LRB-
TPC ||| S:515 E:518 ||| NNP
) ||| S:518 E:519 ||| -RRB-
.  ||| S:519 E:521 ||| .
On  ||| S:521 E:524 ||| IN
the  ||| S:524 E:528 ||| DT
other  ||| S:528 E:534 ||| JJ
hand ||| S:534 E:538 ||| NN
,  ||| S:538 E:540 ||| ,
negative  ||| S:540 E:549 ||| JJ
symptoms  ||| S:549 E:558 ||| NNS
are  ||| S:558 E:562 ||| VBP
associated  ||| S:562 E:573 ||| VBN
with  ||| S:573 E:578 ||| IN
a  ||| S:578 E:580 ||| DT
prefrontal  ||| S:580 E:591 ||| JJ
hypoactivity  ||| S:591 E:604 ||| NN
and  ||| S:604 E:608 ||| CC
the  ||| S:608 E:612 ||| DT
efficiency  ||| S:612 E:623 ||| NN
of  ||| S:623 E:626 ||| IN
pharmacological  ||| S:626 E:642 ||| JJ
treatments  ||| S:642 E:653 ||| NNS
is  ||| S:653 E:656 ||| VBZ
frequently  ||| S:656 E:667 ||| RB
partial ||| S:667 E:674 ||| JJ
.  ||| S:674 E:676 ||| .
Repetitive  ||| S:676 E:687 ||| FW
transcranial  ||| S:687 E:700 ||| FW
magnetic  ||| S:700 E:709 ||| FW
stimulation  ||| S:709 E:721 ||| FW
( ||| S:721 E:722 ||| -LRB-
rTMS ||| S:722 E:726 ||| NNP
)  ||| S:726 E:728 ||| -RRB-
is  ||| S:728 E:731 ||| VBZ
a  ||| S:731 E:733 ||| DT
non-invasive  ||| S:733 E:746 ||| JJ
brain  ||| S:746 E:752 ||| NN
stimulation  ||| S:752 E:764 ||| NN
tool  ||| S:764 E:769 ||| NN
with  ||| S:769 E:774 ||| IN
excellent  ||| S:774 E:784 ||| JJ
tolerability  ||| S:784 E:797 ||| NN
and  ||| S:797 E:801 ||| CC
safety ||| S:801 E:807 ||| NN
.  ||| S:807 E:809 ||| .
Given  ||| S:809 E:815 ||| VBN
its  ||| S:815 E:819 ||| PRP$
hypothesized  ||| S:819 E:832 ||| JJ
mechanisms  ||| S:832 E:843 ||| NNS
of  ||| S:843 E:846 ||| IN
action  ||| S:846 E:853 ||| NN
and  ||| S:853 E:857 ||| CC
the  ||| S:857 E:861 ||| DT
clinical  ||| S:861 E:870 ||| JJ
beneficial  ||| S:870 E:881 ||| JJ
effects  ||| S:881 E:889 ||| NNS
obtained  ||| S:889 E:898 ||| VBN
in  ||| S:898 E:901 ||| IN
several  ||| S:901 E:909 ||| JJ
types  ||| S:909 E:915 ||| NNS
of  ||| S:915 E:918 ||| IN
pathology  ||| S:918 E:928 ||| NNS
( ||| S:928 E:929 ||| -LRB-
Aleman  ||| S:929 E:936 ||| NNP
et  ||| S:936 E:939 ||| NNP
al.  ||| S:939 E:943 ||| CD
2007 ||| S:943 E:947 ||| CD
) ||| S:947 E:948 ||| -RRB-
,  ||| S:948 E:950 ||| ,
the  ||| S:950 E:954 ||| DT
efficacy  ||| S:954 E:963 ||| NN
of  ||| S:963 E:966 ||| IN
rTMS  ||| S:966 E:971 ||| NNP
has  ||| S:971 E:975 ||| VBZ
been  ||| S:975 E:980 ||| VBN
investigated  ||| S:980 E:993 ||| VBN
for  ||| S:993 E:997 ||| IN
drug-resistant  ||| S:997 E:1012 ||| NNP
SCH  ||| S:1012 E:1016 ||| NNP
symptoms.  ||| S:1016 E:1026 ||| VBZ
our  ||| S:1026 E:1030 ||| PRP$
objective  ||| S:1030 E:1040 ||| NN
is  ||| S:1040 E:1043 ||| VBZ
to  ||| S:1043 E:1046 ||| TO
expose  ||| S:1046 E:1053 ||| VB
the  ||| S:1053 E:1057 ||| DT
knowledge  ||| S:1057 E:1067 ||| NN
concerning  ||| S:1067 E:1078 ||| VBG
the  ||| S:1078 E:1082 ||| DT
rTMS  ||| S:1082 E:1087 ||| JJ
use  ||| S:1087 E:1091 ||| NN
in  ||| S:1091 E:1094 ||| IN
the  ||| S:1094 E:1098 ||| DT
treatment  ||| S:1098 E:1108 ||| NN
of  ||| S:1108 E:1111 ||| IN
these  ||| S:1111 E:1117 ||| DT
symptoms  ||| S:1117 E:1126 ||| NNS
and  ||| S:1126 E:1130 ||| CC
to  ||| S:1130 E:1133 ||| TO
purpose  ||| S:1133 E:1141 ||| VB
a  ||| S:1141 E:1143 ||| DT
critical  ||| S:1143 E:1152 ||| JJ
analysis  ||| S:1152 E:1161 ||| NN
of  ||| S:1161 E:1164 ||| IN
these  ||| S:1164 E:1170 ||| DT
data.  ||| S:1170 E:1176 ||| CD
a  ||| S:1176 E:1178 ||| DT
systematic  ||| S:1178 E:1189 ||| JJ
review  ||| S:1189 E:1196 ||| NN
of  ||| S:1196 E:1199 ||| IN
the  ||| S:1199 E:1203 ||| DT
literature  ||| S:1203 E:1214 ||| NN
has  ||| S:1214 E:1218 ||| VBZ
been  ||| S:1218 E:1223 ||| VBN
conducted  ||| S:1223 E:1233 ||| VBN
using  ||| S:1233 E:1239 ||| VBG
NIH  ||| S:1239 E:1243 ||| NNP
Pubmed ||| S:1243 E:1249 ||| NNP
.  ||| S:1249 E:1251 ||| .
The  ||| S:1251 E:1255 ||| DT
following  ||| S:1255 E:1265 ||| JJ
search  ||| S:1265 E:1272 ||| NN
terms  ||| S:1272 E:1278 ||| NNS
were  ||| S:1278 E:1283 ||| VBD
used ||| S:1283 E:1287 ||| VBN
:  ||| S:1287 E:1289 ||| :
TMS  ||| S:1289 E:1293 ||| NNP
-  ||| S:1293 E:1295 ||| :
rTMS  ||| S:1295 E:1300 ||| SYM
-  ||| S:1300 E:1302 ||| :
Schizophrenia  ||| S:1302 E:1316 ||| NNP
-  ||| S:1316 E:1318 ||| :
negative  ||| S:1318 E:1327 ||| JJ
symptoms  ||| S:1327 E:1336 ||| NNS
-  ||| S:1336 E:1338 ||| :
hallucinations.  ||| S:1338 E:1354 ||| CD
concerning  ||| S:1354 E:1365 ||| VBG
the  ||| S:1365 E:1369 ||| DT
treatment  ||| S:1369 E:1379 ||| NN
of  ||| S:1379 E:1382 ||| IN
AH ||| S:1382 E:1384 ||| NNP
,  ||| S:1384 E:1386 ||| ,
16  ||| S:1386 E:1389 ||| CD
publications  ||| S:1389 E:1402 ||| NNS
and  ||| S:1402 E:1406 ||| CC
4  ||| S:1406 E:1408 ||| CD
meta  ||| S:1408 E:1413 ||| CD
analyses  ||| S:1413 E:1422 ||| NNS
were  ||| S:1422 E:1427 ||| VBD
selected ||| S:1427 E:1435 ||| VBN
.  ||| S:1435 E:1437 ||| .
For  ||| S:1437 E:1441 ||| IN
the  ||| S:1441 E:1445 ||| DT
negative  ||| S:1445 E:1454 ||| JJ
symptoms ||| S:1454 E:1462 ||| NNS
,  ||| S:1462 E:1464 ||| ,
we  ||| S:1464 E:1467 ||| PRP
retained  ||| S:1467 E:1476 ||| VBD
16  ||| S:1476 E:1479 ||| CD
studies  ||| S:1479 E:1487 ||| NNS
and  ||| S:1487 E:1491 ||| CC
3  ||| S:1491 E:1493 ||| CD
meta  ||| S:1493 E:1498 ||| CD
analyses ||| S:1498 E:1506 ||| NNS
.  ||| S:1506 E:1508 ||| .
The  ||| S:1508 E:1512 ||| DT
most  ||| S:1512 E:1517 ||| RBS
extensively  ||| S:1517 E:1529 ||| JJ
investigated  ||| S:1529 E:1542 ||| JJ
application  ||| S:1542 E:1554 ||| NN
for  ||| S:1554 E:1558 ||| IN
rTMS  ||| S:1558 E:1563 ||| JJ
in  ||| S:1563 E:1566 ||| IN
SCH  ||| S:1566 E:1570 ||| NNP
is  ||| S:1570 E:1573 ||| VBZ
the  ||| S:1573 E:1577 ||| DT
use  ||| S:1577 E:1581 ||| NN
of  ||| S:1581 E:1584 ||| IN
low-frequency  ||| S:1584 E:1598 ||| JJ
stimulation  ||| S:1598 E:1610 ||| NN
to  ||| S:1610 E:1613 ||| TO
the  ||| S:1613 E:1617 ||| DT
left  ||| S:1617 E:1622 ||| JJ
TPC  ||| S:1622 E:1626 ||| NN
with  ||| S:1626 E:1631 ||| IN
the  ||| S:1631 E:1635 ||| DT
aim  ||| S:1635 E:1639 ||| NN
to  ||| S:1639 E:1642 ||| TO
improve  ||| S:1642 E:1650 ||| VB
AH  ||| S:1650 E:1653 ||| JJ
symptomatology ||| S:1653 E:1667 ||| NN
.  ||| S:1667 E:1669 ||| .
When  ||| S:1669 E:1674 ||| WRB
compared  ||| S:1674 E:1683 ||| VBN
to  ||| S:1683 E:1686 ||| TO
sham ||| S:1686 E:1690 ||| VB
,  ||| S:1690 E:1692 ||| ,
this  ||| S:1692 E:1697 ||| DT
type  ||| S:1697 E:1702 ||| NN
of  ||| S:1702 E:1705 ||| IN
acute  ||| S:1705 E:1711 ||| JJ
course  ||| S:1711 E:1718 ||| NN
of  ||| S:1718 E:1721 ||| IN
rTMS  ||| S:1721 E:1726 ||| NNP
has  ||| S:1726 E:1730 ||| VBZ
been  ||| S:1730 E:1735 ||| VBN
proven  ||| S:1735 E:1742 ||| VBN
to  ||| S:1742 E:1745 ||| TO
induce  ||| S:1745 E:1752 ||| VB
a  ||| S:1752 E:1754 ||| DT
substantial  ||| S:1754 E:1766 ||| JJ
and  ||| S:1766 E:1770 ||| CC
significant  ||| S:1770 E:1782 ||| JJ
reduction  ||| S:1782 E:1792 ||| NN
in  ||| S:1792 E:1795 ||| IN
AH ||| S:1795 E:1797 ||| NNP
.  ||| S:1797 E:1799 ||| .
But  ||| S:1799 E:1803 ||| CC
this  ||| S:1803 E:1808 ||| DT
effect  ||| S:1808 E:1815 ||| NN
does  ||| S:1815 E:1820 ||| VBZ
not  ||| S:1820 E:1824 ||| RB
seem  ||| S:1824 E:1829 ||| VB
long-lasting  ||| S:1829 E:1842 ||| JJ
and  ||| S:1842 E:1846 ||| CC
maintenance  ||| S:1846 E:1858 ||| NN
protocols  ||| S:1858 E:1868 ||| NNS
must  ||| S:1868 E:1873 ||| MD
be  ||| S:1873 E:1876 ||| VB
developed ||| S:1876 E:1885 ||| VBN
.  ||| S:1885 E:1887 ||| .
Concerning  ||| S:1887 E:1898 ||| VBG
negative  ||| S:1898 E:1907 ||| JJ
symptoms ||| S:1907 E:1915 ||| NNS
,  ||| S:1915 E:1917 ||| ,
the  ||| S:1917 E:1921 ||| DT
results  ||| S:1921 E:1929 ||| NNS
are  ||| S:1929 E:1933 ||| VBP
less  ||| S:1933 E:1938 ||| RBR
solid  ||| S:1938 E:1944 ||| JJ
but  ||| S:1944 E:1948 ||| CC
we  ||| S:1948 E:1951 ||| PRP
find  ||| S:1951 E:1956 ||| VBP
some  ||| S:1956 E:1961 ||| DT
works  ||| S:1961 E:1967 ||| NNS
which  ||| S:1967 E:1973 ||| WDT
demonstrate  ||| S:1973 E:1985 ||| VBP
an  ||| S:1985 E:1988 ||| DT
improvement  ||| S:1988 E:2000 ||| NN
of  ||| S:2000 E:2003 ||| IN
these  ||| S:2003 E:2009 ||| DT
symptoms  ||| S:2009 E:2018 ||| NNS
while  ||| S:2018 E:2024 ||| IN
various  ||| S:2024 E:2032 ||| JJ
stimulation  ||| S:2032 E:2044 ||| NN
parameters  ||| S:2044 E:2055 ||| NNS
were  ||| S:2055 E:2060 ||| VBD
used ||| S:2060 E:2064 ||| VBN
.  ||| S:2064 E:2066 ||| .
Recently ||| S:2066 E:2074 ||| RB
,  ||| S:2074 E:2076 ||| ,
new  ||| S:2076 E:2080 ||| JJ
parameters  ||| S:2080 E:2091 ||| NNS
of  ||| S:2091 E:2094 ||| IN
stimulation  ||| S:2094 E:2106 ||| NN
in  ||| S:2106 E:2109 ||| IN
particular  ||| S:2109 E:2120 ||| JJ
the  ||| S:2120 E:2124 ||| DT
theta  ||| S:2124 E:2130 ||| JJ
burst  ||| S:2130 E:2136 ||| NN
stimulation  ||| S:2136 E:2148 ||| NNS
have  ||| S:2148 E:2153 ||| VBP
permitted  ||| S:2153 E:2163 ||| VBN
us  ||| S:2163 E:2166 ||| PRP
to  ||| S:2166 E:2169 ||| TO
obtain  ||| S:2169 E:2176 ||| VB
larger  ||| S:2176 E:2183 ||| JJR
effects  ||| S:2183 E:2191 ||| NNS
with  ||| S:2191 E:2196 ||| IN
longer  ||| S:2196 E:2203 ||| JJR
duration ||| S:2203 E:2211 ||| NN
.  ||| S:2211 E:2213 ||| .
The  ||| S:2213 E:2217 ||| DT
interest  ||| S:2217 E:2226 ||| NN
of  ||| S:2226 E:2229 ||| IN
these  ||| S:2229 E:2235 ||| DT
new  ||| S:2235 E:2239 ||| JJ
parameters  ||| S:2239 E:2250 ||| NNS
will  ||| S:2250 E:2255 ||| MD
be  ||| S:2255 E:2258 ||| VB
discussed  ||| S:2258 E:2268 ||| VBN
here.  ||| S:2268 E:2274 ||| CD
overall ||| S:2274 E:2281 ||| JJ
,  ||| S:2281 E:2283 ||| ,
rTMS  ||| S:2283 E:2288 ||| JJ
studies  ||| S:2288 E:2296 ||| NNS
have  ||| S:2296 E:2301 ||| VBP
demonstrated  ||| S:2301 E:2314 ||| VBN
some  ||| S:2314 E:2319 ||| DT
promise  ||| S:2319 E:2327 ||| NN
in  ||| S:2327 E:2330 ||| IN
the  ||| S:2330 E:2334 ||| DT
treatment  ||| S:2334 E:2344 ||| NN
of  ||| S:2344 E:2347 ||| IN
SCH ||| S:2347 E:2350 ||| NNP
.  ||| S:2350 E:2352 ||| .
However ||| S:2352 E:2359 ||| RB
,  ||| S:2359 E:2361 ||| ,
more  ||| S:2361 E:2366 ||| JJR
research  ||| S:2366 E:2375 ||| NN
is  ||| S:2375 E:2378 ||| VBZ
required  ||| S:2378 E:2387 ||| VBN
to  ||| S:2387 E:2390 ||| TO
enhance  ||| S:2390 E:2398 ||| VB
rTMS  ||| S:2398 E:2403 ||| JJ
efficacy  ||| S:2403 E:2412 ||| NN
and  ||| S:2412 E:2416 ||| CC
increase  ||| S:2416 E:2425 ||| VB
its  ||| S:2425 E:2429 ||| PRP$
beneficial  ||| S:2429 E:2440 ||| JJ
effect  ||| S:2440 E:2447 ||| NN
duration  ||| S:2447 E:2456 ||| NN
and  ||| S:2456 E:2460 ||| CC
to  ||| S:2460 E:2463 ||| TO
test  ||| S:2463 E:2468 ||| VB
new  ||| S:2468 E:2472 ||| JJ
therapeutic  ||| S:2472 E:2484 ||| JJ
strategies  ||| S:2484 E:2495 ||| NNS
in  ||| S:2495 E:2498 ||| IN
this  ||| S:2498 E:2503 ||| DT
topic ||| S:2503 E:2508 ||| NN
.  ||| S:2508 E:2510 ||| .
